The Clinical Study of the Treatment of the CT-guided Percutaneous Radiofrequency Ablation in Lung Cancer
|Keywords||Radiofrequency ablation Non - small cell lung cancer Lung metastasis|
Objective: To evaluate CT-guided percutaneous radiofrequency ablation of lung tumors feasibility, safety and target tumor complete remission rate and median survival time, and radiofrequency ablation of lung tumors overall survival and tumor survival rate . Materials and Methods: 73 cases of non-small cell lung cancer and lung metastasis in cancer patients due to old age, general condition, heart and lung function can not tolerate or are not suitable for surgery, chemotherapy, radiotherapy CT-guided percutaneous radiofrequency ablation. Postoperative chest CT judge ablation is successful and the discovery of the presence or absence of complications. Every 3 months follow-up after last until at least 2 years, analysis of tumor response rate and median survival time (Median Survival Time, MST), while using the Kaplan-Meier analysis of overall survival and tumor-related survival rate. Results: 73 patients with a total of 78 radiofrequency ablation were successfully completed. No surgery-related deaths occurred. Complications, including nine cases of pneumothorax, chest pain, 15 cases, 13 cases of fever, pulmonary hemorrhage five cases of pleural effusion in 1 case. The average number of hospital days 3 days (2-12). One year after the follow-up to radiofrequency ablation, tumor reached complete remission of 57 cases (86%) of 9 patients (14%) local tumor recurrence incomplete ablation. NSCLC and lung metastasis median survival time was 28.33 months, 24 months. To the end of the follow-up period, 51 patients died. Due to the tumor progression killed NSCLC36 cases, 15 cases of lung metastases. The other cause of death in NSCLC include: two cases of heart failure, myocardial infarction, cerebral infarction, respiratory failure two cases. NSCLC patients and 2-year overall survival rate were 93%, 56%; lung metastasis in patients with 1 - and 2-year overall survival rates were 78%, 37%. NSCLC patients with tumors and 2-year survival rates were 94%, 61%. Stage I NSCLC patients and 2-year overall survival rate was 100%, 82%. Conclusion: Radiofrequency ablation of lung tumors technology as a new minimally invasive techniques, with a safe, minimally invasive, and simple operation. The technology of patient injury, fewer complications, faster recovery after treatment, suitable for general condition, heart and lung function can not tolerate or are not suitable for surgery, chemotherapy, radiation therapy of NSCLC patients, also applies to the palliative treatment of patients with pulmonary metastases. The treatment method can not tolerate surgery or not suitable for surgery, as well as put the undesirable effect of chemotherapy in patients with lung cancer, a new treatment, short-term efficacy, but its long-term effect needs further observation.